C4 Therapeutics, Inc. (CCCC) has a negative trailing P/E of -2.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 8.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -44.36%, forward earnings yield 12.08%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 60/100 with 4/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -24.0 | 0.00 | -4.73 | 19.47 | - |
| 2019 | -32.1 | 1.26 | -9.79 | 51.25 | - |
| 2020 | -21.5 | -0.23 | 5.08 | 42.98 | - |
| 2021 | -17.7 | -0.97 | 3.81 | 32.38 | - |
| 2022 | -2.2 | -0.05 | 1.00 | 9.27 | - |
| 2023 | -2.1 | -1.11 | 1.14 | 13.51 | - |
| 2024 | -2.4 | 0.06 | 1.16 | 7.02 | - |
| 2025 | -1.5 | 0.09 | 0.62 | 4.40 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-1.06 | $19.36M | $-15.71M | -81.1% |
| 2019 | $-0.79 | $21.38M | $-34.1M | -159.5% |
| 2020 | $-1.54 | $33.2M | $-66.34M | -199.8% |
| 2021 | $-1.87 | $45.79M | $-86.04M | -187.9% |
| 2022 | $-2.59 | $31.1M | $-126.5M | -406.8% |
| 2023 | $-2.67 | $20.76M | $-132.49M | -638.3% |
| 2024 | $-1.52 | $35.58M | $-105.32M | -296% |
| 2025 | $-1.27 | $35.95M | $-104.99M | -292.1% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.09 | $-1.23 – $-0.94 | $21.62M | $21.62M – $21.62M | 4 |
| 2027 | $-0.99 | $-1.08 – $-0.88 | $21.62M | $21.62M – $21.62M | 4 |
| 2028 | $-1.29 | $-2.23 – $-0.72 | $29.08M | $29.08M – $29.08M | 6 |
| 2029 | $0.33 | $0.33 – $0.33 | $623.58M | $623.58M – $623.58M | 4 |
| 2030 | $4.03 | $4.03 – $4.03 | $1.99B | $1.99B – $1.99B | 2 |
